"We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer," researchers said Kimberlee Speakman is a digital writer at PEOPLE. She has been ...

I couldn't believe it worked that quick, to be honest," Knolmayer told CBS News. He's part of an immunotherapy study that could fundamentally change the way certain cancers are treated.

A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab.

Maureen Sideris, seated, with her sister Marion, receiving the 8th of 9 immunotherapy infusions during successful treatment for early-stage gastroesophageal junction cancer at Memorial Sloan Kettering ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an immunotherapy trial offered stunning results. By Gina Kolata When a person ...

Immunotherapy with dostarlimab enabled 80% of patients with mismatch repair-deficient (MMRd) stage 1–3 solid tumors to avoid surgery, radiation, and chemotherapy after six months, preserving ...

Now, researchers from the US claim a new immunotherapy-based treatment could shrink tumours without chemotherapy or surgery. Immunotherapy is often used in conjunction with chemotherapy or surgery.

Nearly 80% of patients who suffered from a variety of cancer types were successfully treated with only immunotherapy, according to a new study published in The New England Journal of Medicine.

Instead, she received just one treatment — immunotherapy — as part of a clinical trial at Memorial Sloan Kettering. It’s been two years since she completed her treatment and she’s in ...

They were given an immunotherapy drug that overrides how the body allows the immune system to block cancer treatments. No other drugs, except for the immunotherapy treatment, dostarlimab ...

Approximately 2-3% of all early-stage solid tumors exhibit dMMR, a genetic flaw that makes tumors highly sensitive to immunotherapy. In metastatic settings, dMMR tumors respond remarkably to PD-1 ...